Factors Associated With Short- and Long-Term Outcomes of Therapy for Crohn’s Disease-Reference-Cited by-同舟云学术

Factors Associated With Short- and Long-Term Outcomes of Therapy for Crohn’s Disease

Published:2015-03 Issue:3 Volume:13 Page:539-547.e2
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Reinisch Walter,Colombel Jean-Frederic,Sandborn William J.,Mantzaris Gerassimos J.,Kornbluth Asher,Adedokun Omoniyi J.,Miller Michael,Tang Kezhen L.,Rutgeerts Paul,Cornillie Freddy

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference17 articles.

1. Treat to target: a proposed new paradigm for the management of Crohn’s disease;Bouguen;Clin Gastroenterol Hepatol,2013

2. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease;Bouguen;Clin Gastroenterol Hepatol,2014

3. Adalimumab induces deep remission in patients with Crohn's disease;Colombel;Clin Gastroenterol Hepatol,2014

4. Composite remission measures in early Crohn’s disease: a post-hoc analysis of the SONIC trial (abstr);Colombel;United Eur Gastro J,2013

5. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial;Cornillie;Gut,2014

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology;Therapeutic Drug Monitoring;2024-04-17

2. Comparing the Effects of Anti-TNF Agent and Ustekinumab on Small Bowel Inflammation in Crohn’s Disease: Inverse Probability Weighting With Stabilized Weights of Propensity Scores;Crohn's & Colitis 360;2024-04-01

3. Controversies in the management of anti-TNF therapy in patients with Crohn’s disease: a Delphi consensus;BMJ Open Gastroenterology;2024-01

4. Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?;Expert Opinion on Biological Therapy;2023-04-03

5. Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial;Clinical Drug Investigation;2023-04